This protocol is a dose escalation study of Ad - hCMV - TK and Ad - hCMV - Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. (clinicaltrials.gov)
Valacyclovir treatment will begin 1 - 3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. (clinicaltrials.gov)
There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells. (clinicaltrials.gov)